STOCK TITAN

Kyntra Bio Reports Third Quarter 2026 Financial Results and Provides Business Update

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

Kyntra Bio (KYNB) reported third-quarter 2026 revenue of $1.762 million and discontinued its oncology programs following insufficient interim efficacy.

Revenue rose from $1.076 million a year earlier. Continuing operations generated $157,000 in income, or $0.04 per share, versus a $13.146 million loss; results included a $14.011 million debt-restructuring gain. The royalty financing restructuring reduced maximum aggregate payments from $125 million to $65 million, leaving $15 million payable after a $42.6 million accelerated payment.

Kyntra plans a Phase 3 roxadustat trial for anemia in lower-risk myelodysplastic syndromes with high transfusion burden in Q1 2027, conditional on a partnership or external capital raise. It discontinued FG-3246 and FG-3180 and expects over $20 million in operating expense savings in 2027 and 2028. Cash, investments and receivables totaled $44.1 million at September 30; Kyntra expects funding into 2028.

Loading...
Loading translation...
11 points · 3 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

2 major · 15 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Major pointRoyalty financing restructuring reduced maximum aggregate payments by $60 million, from $125 million to $65 million. 4.3× market cap
  • Major point. Forward-looking: it has not happened yet and may not happen.Program termination is expected to save over $20 million in operating expenses in 2027 and 2028.
  • Major pointThird-quarter results included a $14.011 million gain on debt restructuring.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Kyntra expects existing cash, investments and receivables to fund operating plans into 2028.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Kyntra plans pivotal roxadustat Phase 3 initiation in Q1 2027 for anemia in lower-risk myelodysplastic syndromes.
  • Moderate pointThird-quarter revenue increased to $1.762 million from $1.076 million a year earlier.
  • Moderate pointThird-quarter continuing operations earned $157,000, or $0.04 per share, versus a $13.146 million loss, or $3.25 per share.
  • Moderate pointNine-month continuing-operations loss narrowed to $3.001 million from $43.594 million a year earlier.
  • Moderate pointNine-month results included a $30.940 million gain on deconsolidation of a subsidiary.
2 minor points
  • Minor pointThird-quarter interest expense declined to $1.632 million from $2.083 million a year earlier.
  • Minor pointTotal liabilities declined to $56.041 million at September 30, 2026, from $115.119 million at December 31, 2025.

Negative

  • Major pointFG-3246 and FG-3180 development discontinued after insufficient efficacy at FG-3246’s pre-specified Phase 2 prostate-cancer interim analysis.
  • Major pointRoyalty restructuring required a $42.6 million accelerated payment to NQ Project Phoebus. 3.1× market cap
  • Moderate pointRoxadustat Phase 3 initiation depends on a strategic partnership or external capital raise.
  • Moderate pointThird-quarter net income fell to $157,000 from $200.636 million; prior-year discontinued operations contributed $213.782 million.
  • Moderate pointThird-quarter operating loss widened to $12.865 million from $5.411 million a year earlier.
  • Moderate pointNine-month revenue declined to $4.026 million from $5.163 million a year earlier.
  • Moderate pointNine-month operating loss widened to $44.258 million from $32.383 million a year earlier.
  • Moderate pointNine-month net loss was $3.067 million, versus $197.672 million net income a year earlier.
  • Moderate pointCash and equivalents declined to $9.905 million from $47.872 million at December 31, 2025.
6 minor points
  • Minor pointRemaining royalty payments are capped at $15 million, funded from 50% of specified Astellas drug-product revenue.
  • Minor pointThird-quarter research and development expense rose to $8.266 million from $1.209 million a year earlier.
  • Minor pointThird-quarter selling, general and administrative expense rose to $5.757 million from $5.295 million a year earlier.
  • Minor pointThird-quarter cost of goods sold was $619,000, versus negative $58,000 a year earlier.
  • Minor pointShort-term investments declined to $30.385 million from $41.106 million at December 31, 2025.
  • Minor pointTotal deficit widened to $28.670 million from $17.005 million at December 31, 2025.

News Explained

The remaining $15 million is payable from 50% of roxadustat revenue Kyntra recognizes from Astellas in Astellas territories excluding Japan; once that cap is reached, the agreement ends and Kyntra retains subsequent EVRENZO royalties in those territories.

Key Figures

Maximum royalty payments: $125 million to $65 million Remaining royalty payment cap: $15 million Accelerated royalty payment: $42.6 million +5 more
Maximum royalty payments
$125 million to $65 million
Amended royalty financing agreement
Remaining royalty payment cap
$15 million
Paid from 50% of qualifying Astellas-territory roxadustat revenue
Accelerated royalty payment
$42.6 million
Payment to NQ Project Phoebus under the amended agreement
Operating expense savings
Over $20 million
Expected in 2027 and 2028 from ending the FG-3246 study
Total revenue
$1.8 million vs. $1.1 million
Third quarter 2026 vs. third quarter 2025
Net income from continuing operations
$0.2 million vs. net loss of $13.1 million
Third quarter 2026 vs. third quarter 2025
Cash, investments, and accounts receivable
$44.1 million
As of September 30, 2026; operating plans expected to be funded into 2028
Planned Phase 3 initiation
1Q 2027
Roxadustat trial; subject to a strategic partnership or external capital raise

Previous Earnings Reports

2 past events · Latest: Aug 13
Same Type 2 events
  1. Aug 13

    Q2 earnings

    24h Move
    +0.1%

    FG-3246 Phase 2 continued enrolling; roxadustat Phase 3 protocol finalized, targeting a 4Q 2026 start.

  2. May 11

    Q1 earnings

    24h Move
    +6.3%

    FG-3246 Phase 2 continued; roxadustat Phase 3 initiation targeted for 2H 2026.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

mcrpc, lr-mds, hif-ph inhibitors, erythropoiesis
4 terms
mcrpc medical
"metastatic castration-resistant prostate cancer (mCRPC)"
mCRPC stands for metastatic castration‑resistant prostate cancer, a form of prostate cancer that has spread beyond the prostate and keeps progressing despite treatments that lower male hormones. It matters to investors because this stage is harder to treat, drives demand for new therapies, and often involves large, expensive clinical trials and regulatory decisions that can strongly influence a drug maker’s future revenue and stock value—think of it as a stubborn problem that creates both medical need and commercial opportunity.
lr-mds medical
"anemia in LR-MDS patients with high transfusion burden (HTB)"
A subtype of myelodysplastic syndromes (MDS) classified as having a lower short-term risk of progressing to acute myeloid leukemia and generally better survival compared with higher‑risk MDS. Risk category is determined by established prognostic scoring systems (for example IPSS or IPSS‑R) that combine factors such as blood counts, percentage of abnormal cells in the bone marrow, and chromosomal abnormalities; lower‑risk patients typically receive treatments focused on managing anemia and symptoms rather than intensive chemotherapy or stem‑cell transplantation. The label LR‑MDS denotes disease category, not a specific treatment or drug, and guides the choice and intensity of clinical management.
hif-ph inhibitors medical
"HIF-PH inhibitors that promote erythropoiesis"
HIF‑PH inhibitors are a class of drugs that block prolyl hydroxylase enzymes, which stabilizes hypoxia‑inducible factors (HIFs) inside cells and increases production of erythropoietin and other proteins that boost red blood cell production and regulate iron. They matter to investors because clinical trial results, regulatory approvals, manufacturing scale and safety data determine commercial opportunity in treating anemia and related conditions, affecting company revenues and stock performance.
erythropoiesis medical
"promote erythropoiesis, or red blood cell production"
The body's process for making red blood cells in the bone marrow, driven by signals such as a hormone that tells immature cells to mature and enter the bloodstream. Think of it as a factory assembly line that builds the blood’s oxygen delivery trucks; when the line speeds up or breaks down it changes demand for drugs, diagnostics and treatments. Investors watch it because therapies that boost or regulate this process can reshuffle market value in hematology, transfusion services and related drugs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
  • Completed restructuring of royalty financing agreement, reducing the maximum aggregate payment obligation by $60 million, with only $15 million in future royalty-backed payments remaining

  • Initiation of the pivotal Phase 3 trial of roxadustat for the treatment of anemia in LR-MDS patients with high transfusion burden (HTB) planned in 1Q 2027, subject to the execution of either a strategic partnership or an external capital raise

  • Decision to discontinue development of FG-3246 and FG-3180 following insufficient efficacy at the pre-specified Phase 2 interim analysis in metastatic castration-resistant prostate cancer (mCRPC), resulting in a reduction of over $20 million in operating expenses in 2027 and 2028

  • Cash, cash equivalents, investments, and accounts receivable of $44.1 million as of September 30, 2026, with a cash runway now into 2028

  • Kyntra Bio to host conference call and webcast presentation today at 5:00 PM ET

SAN FRANCISCO, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today reported financial results for the third quarter 2026 and provided an update on the company’s recent developments.

“Following a pre-planned interim analysis showing insufficient efficacy, we have made the decision to terminate the FG-3246 Phase 2 trial,” said Thane Wettig, Chief Executive Officer of Kyntra Bio. “We continue to work towards the completion of our transformation to a pure-play, rare disease company laser-focused on the initiation and execution of the Phase 3 roxadustat trial. The unmet medical need and corresponding multi-billion-dollar commercial opportunity in LR-MDS is significant. Subject to the execution of either a strategic partnership or an external capital raise, we plan on initiating the pivotal Phase 3 trial in the first quarter of 2027.”

      Key Highlights of Third Quarter, Recent Developments, and Upcoming Milestones

Roxadustat

  • Initiation of the pivotal Phase 3 trial of roxadustat for the treatment of anemia in patients with LR-MDS and HTB planned in the first quarter of 2027, subject to the execution of either a strategic partnership or an external capital raise.

FG-3246 (CD46 Targeting ADC) and FG-3180 (CD46 Targeting PET Imaging Agent)

  • Following a pre-specified interim analysis of the ongoing Phase 2 study of FG-3246 in mCRPC, the Company decided to close enrollment in the study and discontinue development of the program.
    • Preliminary efficacy results at the interim analysis did not meet the threshold required to support continued development.
  • The Company plans to complete the close-out of the study over the coming months and will cancel all planned future investment in the program.
  • The Company expects to save over $20 million in operating expenses in 2027 and 2028 from the termination of the study.

Corporate

  • In August 2026, the company signed an amendment and restatement of its existing royalty financing agreement with NQ Project Phoebus, L.P., materially reducing its payment obligations under the agreement in exchange for an accelerated upfront payment. The amendment included the following terms:
    • Reduction of the maximum aggregate payments under the agreement from $125 million to $65 million, including the $42.6 million accelerated payment to NQ Project Phoebus, L.P., bringing total payments made to date to $50 million, a full return of NQ Project Phoebus, L.P.’s invested capital.
    • Remaining payments, capped at $15 million, to be paid from 50% of the roxadustat drug product revenue Kyntra Bio recognizes from Astellas in the Astellas territories excluding Japan.
    • Once the $15 million cap is reached, the amended agreement will terminate, with Kyntra Bio retaining all subsequent EVRENZO™ royalties in the Astellas territories.
  • Appointed Andrew E. Singer, MBA to the Board of Directors.

Financial

  • Total revenue from continuing operations for the third quarter of 2026 was $1.8 million, as compared to $1.1 million for the third quarter of 2025.
  • Net income from continuing operations for the third quarter of 2026 was $0.2 million, or $0.04 net income per basic and diluted share, compared to a net loss of $13.1 million, or $3.25 net loss per basic and diluted share, one year ago.
  • As of September 30, 2026, Kyntra Bio reported $44.1 million in cash, cash equivalents, investments, and accounts receivable.
  • The Company expects its cash, cash equivalents, investments, and accounts receivable to be sufficient to fund operating plans into 2028.

Conference Call and Webcast Presentation
Kyntra Bio management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the conference call here. To access the call by phone, please register here, and you will be provided with dial in details. A replay of the webcast will also be available for a limited time on the Events & Presentations page on Kyntra Bio’s website.

About Roxadustat
Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin, improved iron absorption and mobilization, and downregulation of hepcidin.

Roxadustat is approved in Europe, Japan, China, and numerous other countries for the treatment of anemia of CKD in adult patients on dialysis (DD) and not on dialysis (NDD). Kyntra Bio has the sole rights to roxadustat in the United States, Canada, Mexico, and in all markets not held by AstraZeneca or licensed to Astellas. Astellas and Kyntra Bio are collaborating on the commercialization of roxadustat for the treatment of anemia in territories including Japan, Europe, Turkey, Russia, and the Commonwealth of Independent States, the Middle East, and South Africa.

Following promising results from the Phase 2/3 MATTERHORN study, the Company is planning to study roxadustat in a pivotal Phase 3 trial in patients with anemia associated with lower-risk myelodysplastic syndromes (LR-MDS) and high transfusion burden (HTB).

About Kyntra Bio
Kyntra Bio is a pure play, rare disease biopharmaceutical company focused on the development of roxadustat for anemia associated with lower-risk myelodysplastic syndromes (LR-MDS). Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in Europe, Japan, China, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company is planning to study roxadustat in a pivotal Phase 3 trial in patients with anemia associated with lower-risk myelodysplastic syndromes (LR-MDS). For more information, please visit www.kyntrabio.com.

Forward-Looking Statements 
This release contains forward-looking statements regarding Kyntra Bio’s strategy, future plans and prospects, including statements regarding its commercial products and clinical programs and those of its partners Fortis and UCSF. These forward-looking statements include, but are not limited to, statements regarding the efficacy, safety, and potential clinical or commercial success of Kyntra Bio products and product candidates, statements under the caption “Recent Highlights and Upcoming Milestones”, statements about regulatory interactions, statements regarding cash, such as the expectation that cash, cash equivalents and accounts receivable will be sufficient to fund Kyntra Bio’s operating plans into 2028, and statements about Kyntra Bio’s plans and objectives. These forward-looking statements are typically identified by use of terms such as “may,” “will”, “should,” “on track,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. Kyntra Bio’s actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress and timing of its various programs, including the enrollment and results from ongoing and potential future clinical trials, and other matters that are described in Kyntra Bio’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, each as filed with the Securities and Exchange Commission (SEC), including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and Kyntra Bio undertakes no obligation to update any forward-looking statement in this press release, except as required by law.

Condensed Consolidated Balance Sheets
(In thousands)

 September 30, 2026  December 31, 2025
 (Unaudited)  (1)
Assets    
Current assets:    
Cash and cash equivalents$9,905  $47,872 
Short-term investments 30,385   41,106 
Accounts receivable, net 3,848   216 
Inventory 3,255   3,743 
Prepaid expenses and other current assets 1,227   6,136 
Total current assets 48,620   99,073 
Long-term investments —   20,160 
Other assets 231   361 
Total assets$48,851  $119,594 
     
Liabilities, stockholders’ equity and non-controlling interests    
Current liabilities:    
Accounts payable$4,581  $3,745 
Accrued and other liabilities 31,005   20,183 
Deferred revenue 6,170   5,314 
Total current liabilities 41,756   29,242 
Product development obligations —   19,560 
Deferred revenue, net of current 2,957   255 
Liability related to sale of future revenues, non-current 11,268   65,980 
Other long-term liabilities 60   82 
Total liabilities 56,041   115,119 
     
Redeemable non-controlling interests 21,480   21,480 
Total stockholders’ deficit attributable to Kyntra Bio (29,190)  (30,038)
Nonredeemable non-controlling interests 520   13,033 
Total deficit (28,670)  (17,005)
Total liabilities, redeemable non-controlling interests and deficit$48,851  $119,594 


(1) The condensed consolidated balance sheet amounts at December 31, 2025 are derived from audited financial statements.

Condensed Consolidated Statements of Operations
(In thousands, except per share data)

 Three Months Ended September 30,  Nine Months Ended September 30, 
 2026  2025  2026  2025 
 (Unaudited) 
Revenue:           
Development and other revenue$99  $119   449   396 
Drug product revenue, net 1,663   957   3,577   4,767 
Total revenue 1,762   1,076   4,026   5,163 
            
Operating costs and expenses:           
Cost of goods sold 619   (58)  4,727   278 
Research and development 8,266   1,209   22,654   16,249 
Selling, general and administrative 5,757   5,295   20,951   20,459 
Restructuring charge (15)  41   (48)  560 
Total operating costs and expenses 14,627   6,487   48,284   37,546 
Loss from operations (12,865)  (5,411)  (44,258)  (32,383)
            
Interest and other, net:           
Interest expense (1,632)  (2,083)  (6,426)  (6,346)
Gain on deconsolidation of subsidiary —   —   30,940   — 
Loss on debt extinguishments —   (6,583)  —   (6,583)
Gain on debt restructuring 14,011   —   14,011   — 
Interest income and other income (expenses), net 643   931   2,731   1,628 
Total interest and other, net 13,022   (7,735)  41,256   (11,301)
            
Income (loss) from continuing operations before income taxes 157   (13,146)  (3,002)  (43,684)
Benefit from income taxes —   —   (1)  (90)
Income (loss) from continuing operations 157   (13,146)  (3,001)  (43,594)
Income (loss) from discontinued operations, net of tax —   213,782   (66)  241,266 
Net income (loss)$157  $200,636  $(3,067) $197,672 
            
Income (loss) from continuing operations per share - basic
and diluted
$0.04  $(3.25) $(0.74) $(10.79)
Income (loss) from discontinued operations per share - basic
and diluted
 —   52.86   (0.02)  59.69 
Net income (loss) per share - basic and diluted$0.04  $49.61  $(0.76) $48.90 
            
Weighted average number of common shares used to
calculate net income (loss) per share:
           
Basic 4,049   4,044   4,048   4,042 
Diluted 4,050   4,044   4,048   4,042 


For Investor Inquiries:

David DeLucia, CFA
Senior Vice President and Chief Financial Officer
ir@kyntrabio.com 


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why did Kyntra Bio discontinue FG-3246 and FG-3180?

Kyntra discontinued the programs after preliminary FG-3246 efficacy results failed to meet the threshold for continued development at the pre-specified Phase 2 interim analysis in metastatic castration-resistant prostate cancer. Enrollment is closing, study close-out is planned over the coming months, and all planned future investment in the program will be canceled.

When does Kyntra Bio plan to start the roxadustat Phase 3 trial?

Kyntra plans to initiate the pivotal trial in the first quarter of 2027, subject to executing either a strategic partnership or an external capital raise. The trial would study anemia in patients with lower-risk myelodysplastic syndromes and high transfusion burden.

How will Kyntra Bio pay its remaining royalty financing obligation?

The remaining payments, capped at $15 million, will come from 50% of roxadustat drug-product revenue Kyntra recognizes from Astellas in Astellas territories excluding Japan. Once that cap is reached, the amended agreement terminates and Kyntra retains all subsequent EVRENZO royalties in the Astellas territories.

Keep reading